Latest news
Iconovo launches improved versions of nasal ICOone inhalers
Iconovo launches improved versions of nasal ICOone. Both inhalers are designed for high technical performance and to minimize the risk of user error.…
Iconovo receives order from Top-10 Pharma company for evaluation of multi-dose inhaler
Iconovo announces that it has received an order from a company revenue wise ranking among the top ten largest pharma companies in the world to evaluate…
Press releases
Nov 30, 2023, 09:30
News
IR
Swedish
Regulatory
Listing Regulation
Corporate Action
Other
Nov 30, 2023, 09:30
News
IR
English
Regulatory
Listing Regulation
Corporate Action
Other
Nov 29, 2023, 14:30
News
IR
Swedish
Regulatory
Listing Regulation
Corporate Information
Nomination Committee
Nov 29, 2023, 14:30
News
IR
English
Regulatory
Listing Regulation
Corporate Information
Nomination Committee
Nov 16, 2023, 11:15
News
IR
English
Corporate Action
Other
Nov 16, 2023, 11:15
News
IR
Swedish
Corporate Action
Other
Oct 31, 2023, 08:30
News
IR
Swedish
Corporate Action
Other
mfn-cus-disclaimer
Oct 27, 2023, 14:00
News
IR
Swedish
Regulatory
Listing Regulation
Corporate Information
General meeting
Raport bolagsstämman
Oct 27, 2023, 08:30
News
IR
Swedish
Regulatory
MAR
Report
Interim
Q3
Oct 17, 2023, 21:15
News
IR
Swedish
Regulatory
Listing Regulation
Corporate Action
Other
mfn-cus-disclaimer
Sep 26, 2023, 23:35
News
IR
Swedish
Regulatory
Listing Regulation
Corporate Information
General meeting
Notice
Sep 26, 2023, 23:30
News
IR
English
Regulatory
MAR
Corporate Action
Shares
Issuance
mfn-cus-top-disclaimer
Sep 26, 2023, 23:30
News
IR
Swedish
Regulatory
MAR
Corporate Action
Shares
Issuance
mfn-cus-top-disclaimer
Sep 26, 2023, 09:15
News
IR
Swedish
Corporate Action
Other
Sep 26, 2023, 09:15
News
IR
English
Corporate Action
Other
Sep 19, 2023, 08:30
News
IR
English
Corporate Action
Other
Sep 19, 2023, 08:30
News
IR
Swedish
Corporate Action
Other
Sep 13, 2023, 12:42
News
IR
Swedish
Corporate Action
Other
Sep 13, 2023, 12:42
News
IR
English
Corporate Action
Other
Possessing a unique combination
of engineering and pharma expertise, Iconovo can provide the optimal combination of customized inhalers and tailored formulations.
ICONOVO AB
VISITING ADDRESS
Ideon, Delta 6 Lund
Ideongatan 3B
POSTAL ADDRESS
Iconovo AB
Ideongatan 3A-B
SE-223 62 LUND
Sweden
CONTACT
Phone: +46 46 275 67 77
Director Business Development and Alliances
Måns Österberg
Mail: mans.osterberg@iconovo.se
Interim CEO
Anders Månsson
Mail: anders.mansson@iconovo.se